Drug - Admelog® (insulin lispro) [Sanofi-Aventis U.S. LLC]
July 2018
Therapeutic area - Insulin
Admelog is approved by the FDA under the New Drug Application (NDA) pathway and is not considered an interchangeable biosimilar to Humalog. Admelog is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus
MHCP Provider Call Center 651-431-2700 or 800-366-5411